TSR2

Across TCGA pan-cancer cohorts, TSR2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TSR2 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TSR2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TSR2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and LSCC are the cancer types where TSR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.940	0.700	.018	22	view →
HNSC	DFS	Median	All	0.860	0.361	.022	6	view →
LSCC	OS	Quartile	All	0.744	0.954	.013	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TSR2–LUAD (OS)

Open the LUAD breakdown →